Improving the Design of Clinical Trials in T1D: Analysis of Data from the Trial Outcome Markers Initiative (TOMI) Collaboration

*With presentations from JDRF, TrialNet and the TOMI-T1D Collaboration*

The Trial Outcome Marker Initiative brings together data from many contributors in the field comprising more than 10,000 individuals with new onset T1D including 2900 from 21 different clinical trials. Analysis of C-peptide, HbA1c and as well as composite outcomes will be discussed which has provided significant insights into designing clinical trials in Stage 3 T1D.

You can register [here](#) and view the full agenda [here](#).